Letter
Clinical Neurology
Robert A. Gross, Yan Yuan, Chris Keran, Janis M. Miyasaki
Summary: The study shows that aHSCT can prevent disability worsening in the majority of multiple sclerosis (MS) patients and induce durable improvement in disability, especially in patients with relapsing-remitting MS. The use of the BEAM + ATG conditioning protocol is associated with a more pronounced suppression of clinical relapses and MRI inflammatory activity.
Article
Immunology
Michael Gernert, Hans-Peter Tony, Matthias Froehlich, Eva Christina Schwaneck, Marc Schmalzing
Summary: This study investigated the use of immunosuppressive medication (IS) after autologous hematopoietic stem cell transplantation (aHSCT) in systemic sclerosis (SSc) patients. The results showed that approximately 60% of SSc patients required IS after aHSCT for disease control. Rituximab was found to be an effective treatment option. Long-term data suggested that aHSCT is safe.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Josefine Ruder, Gianna Dinner, Aleksandra Maceski, Ernesto Berenjeno-Correa, Antonia Maria Mueller, Ilijas Jelcic, Jens Kuhle, Roland Martin
Summary: Autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for multiple sclerosis (MS), which normalizes pathological processes and enhances beneficial processes. Biomarker analysis of MS patients undergoing aHSCT showed that serum levels of CXCL10, NfL, and GFAP significantly increased one month after transplantation, but returned to normal after one to two years. Levels of GFAP in cerebrospinal fluid (CSF) increased 24 months after aHSCT, indicating sustained astroglia activation. Other CSF markers remained relatively stable.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Correction
Clinical Neurology
G. Boffa, L. Massacesi, M. Inglese
Summary: Despite equal numbers of women and men completing neurology residencies, the majority of AAN members are still men. Based on historical imbalance, it is estimated that women and men will be equal in number among neurologist AAN membership by 2047.
Article
Clinical Neurology
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, Fredrik Piehl
Summary: This study compares the safety outcomes of different induction therapies for multiple sclerosis patients. It found a higher incidence of thyroid disease in patients treated with alemtuzumab and AHSCT, with a higher incidence of infection in AHSCT-treated patients compared to both alemtuzumab and noninduction therapies. The incidence of nonthyroid autoimmune disease was low for both therapies.
Article
Medicine, General & Internal
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Vincenzo Cimino, Giuseppe Milone
Summary: Multiple sclerosis (MS) is a chronic disease of the central nervous system that can lead to lifelong disability. Despite various treatment options, some patients still face severe symptoms and long-term disability risk. Recent studies have shown that autologous hematopoietic stem cell transplantation (AHSCT) is a highly effective and relatively safe treatment option for highly active MS.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Clinical Neurology
Alice Mariottini, Leonardo Marchi, Chiara Innocenti, Maria Di Cristinzi, Matteo Pasca, Stefano Filippini, Alessandro Barilaro, Claudia Mechi, Arianna Fani, Benedetta Mazzanti, Tiziana Biagioli, Francesca Materozzi, Riccardo Saccardi, Luca Massacesi, Anna Maria Repice
Summary: The study found that intermediate-intensity AHSCT significantly reduced neurofilament light chain concentration in aggressive MS patients, reducing axonal damage occurrence. There was no clear association between sNfL levels and treatment response, indicating sNfL's sensitivity to inflammatory activity.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Giacomo Boffa, Elvira Sbragia, Anna Maria Raiola, Riccardo Varaldo, Elisabetta Capello, Paolo Gallo, Franco Granella, Gianluigi Mancardi, Matilde Inglese
Summary: Autologous haematopoietic stem cell transplantation (aHSCT) could be considered as a rescue treatment for multiple sclerosis patients with persistent disease activity during alemtuzumab treatment, as short-term safety and efficacy data showed good outcomes.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Oncology
Chuanying Geng, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian, Guangzhong Yang, Wenming Chen
Summary: This study found that ASCT may improve the overall survival (OS) and progression-free survival (PFS) of CD56 positive patients, while not impacting the survival of CD56 negative patients.
Article
Clinical Neurology
Alice Mariottini, Giovanni Bulgarini, Benedetta Forci, Chiara Innocenti, Fabrizia Mealli, Alessandra Mattei, Chiara Ceccarelli, Anna Maria Repice, Alessandro Barilaro, Claudia Mechi, Riccardo Saccardi, Luca Massacesi
Summary: The study demonstrates that for patients with secondary-progressive multiple sclerosis (SP-MS), AHSCT is more effective than cyclophosphamide (Cy) in reducing relapse activity, but there is no significant difference between the two in terms of disability progression. AHSCT is beneficial for reducing relapses, but disability progression in SP-MS is more likely driven by noninflammatory neurodegeneration.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Alice Mariottini, Eleonora De Matteis, Maria Teresa Cencioni, Paolo A. A. Muraro
Summary: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly recognized as a treatment option for multiple sclerosis (MS). Recent studies have confirmed the persistent anti-inflammatory effects and improvement in disease course in patients with relapsing-remitting MS. Further research is needed to determine the role of AHSCT in other forms of MS.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2023)
Review
Oncology
Yuan Yang, Jiang Ji, Zengwei Tang, Bing Han
Summary: This study compares the efficacy and safety of EPAG+IST and haplo-HSCT in treating severe aplastic anemia. The results show that EPAG+IST has comparable overall response rate and 1-/2-year overall survival, but lower complete response rate compared to haplo-HSCT. Patients treated with haplo-HSCT may experience a higher incidence of GVHD, while those treated with EPAG+IST may have more relapses or clone evolution.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Jayden A. Smith, Alexandra M. Nicaise, Rosana-Bristena Ionescu, Regan Hamel, Luca Peruzzotti-Jametti, Stefano Pluchino
Summary: Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. While current treatments for progressive MS are limited, stem cell transplantation shows promise in providing neurotrophic support, immunomodulation, and cell replacement to combat chronic neuroinflammation.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Clinical Neurology
J. Das, J. A. Snowden, J. Burman, M. S. Freedman, H. Atkins, M. Bowman, R. K. Burt, R. Saccardi, C. Innocenti, S. Mistry, P. J. Laud, H. Jessop, B. Sharrack
Summary: The study demonstrates that AHSCT as a first-line DMT for patients with 'aggressive' MS is safe and effective in inducing rapid and sustained remission. Patients showed improvement in EDSS score and no further relapses were reported during follow-up.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Review
Clinical Neurology
Fardin Nabizadeh, Kasra Pirahesh, Nazanin Rafiei, Fatemeh Afrashteh, Mona Asghari Ahmadabad, Aram Zabeti, Omid Mirmosayyeb
Summary: This study conducted a comprehensive systematic review and meta-analysis to investigate the efficacy and safety of autologous hematopoietic stem-cell transplantation (AHSCT) in patients with multiple sclerosis (MS). The results showed that AHSCT led to a significant decrease in Expanded Disability Status Scale (EDSS) score and annualized relapse rate. Most patients remained relapse-free after AHSCT and the overall survival rate was high.
NEUROLOGY AND THERAPY
(2022)
Article
Clinical Neurology
Barbora Srpova, Lukas Sobisek, Klara Novotna, Tomas Uher, Lucie Friedova, Manuela Vaneckova, Jan Krasensky, Eva Kubala Havrdova, Dana Horakova
Summary: The study identified that employment status of multiple sclerosis patients is independently associated with EDSS score, walking ability, cognitive performance, and MRI volumetric parameters.
NEUROLOGICAL SCIENCES
(2022)
Correction
Computer Science, Interdisciplinary Applications
Edward De Brouwer, Thijs Becker, Yves Moreau, Eva Kubala Havrdova, Maria Trojano, Sara Eichau, Serkan Ozakbas, Marco Onofrj, Pierre Grammond, Jens Kuhle, Ludwig Kappos, Patrizia Sola, Elisabetta Cartechini, Jeannette Lechner-Scott, Raed Alroughani, Oliver Gerlach, Tomas Kalincik, Franco Granella, Francois Grand'Maison, Roberto Bergamaschi, Maria Jose Sa, Bart Van Wijmeersch, Aysun Soysal, Jose Luis Sanchez-Menoyo, Claudio Solaro, Cavit Boz, Gerardo Iuliano, Katherine Buzzard, Eduardo Aguera-Morales, Murat Terzi, Tamara Castillo Trivio, Daniele Spitaleri, Vincent Van Pesch, Vahid Shaygannejad, Fraser Moore, Celia Oreja-Guevara, Davide Maimone, Riadh Gouider, Tunde Csepany, Cristina Ramo-Tello, Liesbet Peeters
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
(2022)
Article
Clinical Neurology
Tomas Uher, Eva Kubala Havrdova, Karolina Vodehnalova, Jan Krasensky, Vaclav Capek, Manuela Vaneckova, Dana Horakova
Summary: The study aimed to investigate the brain changes and radiological disease activity in women with multiple sclerosis (MS) during pregnancy and postpartum periods. The results showed that women in the postpartum period had increased T2 lesion volume and accelerated brain volume loss, which is important for treatment decision-making and clinical trial design.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Massimo Filippi, Romano Danesi, Tobias Derfuss, Martin Duddy, Paolo Gallo, Ralf Gold, Eva Kubala Havrdova, Barbara Kornek, Francesco Sacca, Mar Tintore, Joerg Weber, Maria Trojano
Summary: Early intervention with high-efficacy disease-modifying therapy (HE DMT) can delay the progression of multiple sclerosis. While not every patient needs HE DMT treatment at the initial stages of the disease, early and unrestricted access to HE DMTs will provide patients with the freedom to choose treatment based on shared decision-making. This will optimize outcomes and improve resource allocation in healthcare systems and society.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Alasdair J. Coles, Joanne L. Jones, Patrick Vermersch, Anthony Traboulsee, Ann D. Bass, Aaron Boster, Andrew Chan, Giancarlo Comi, Oscar Fernandez, Gavin Giovannoni, Eva Kubala Havrdova, Christopher LaGanke, Xavier Montalban, Celia Oreja-Guevara, Fredrik Piehl, Heinz Wiendl, Tjalf Ziemssen
Summary: In individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab, preexisting or treatment-emergent autoimmunity does not increase the risk of subsequent autoimmune disease. Additionally, thyroid autoimmunity after alemtuzumab treatment does not lead to an increased risk of non-thyroid autoimmune adverse events. Post-marketing safety data contribute to a comprehensive understanding of the benefits and risks of alemtuzumab in the field of MS.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Economics
Timothy Spelman, William L. Herring, Yuanhui Zhang, Michael Tempest, Isobel Pearson, Ulrich Freudensprung, Carlos Acosta, Thibaut Dort, Robert Hyde, Eva Havrdova, Dana Horakova, Maria Trojano, Giovanna De Luca, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi, Csilla Rozsa, Cavit Boz, Raymond Hupperts, Vincent Van Pesch, Celia Oreja-Guevara, Anneke van der Walt, Vilija G. Jokubaitis, Tomas Kalincik, Helmut Butzkueven
Summary: This study compared the effectiveness and cost-effectiveness of switching to natalizumab or fingolimod for patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies. The results showed that escalating therapy to natalizumab resulted in higher quality-adjusted life-years and lower costs compared to fingolimod for UK patients.
Review
Biochemistry & Molecular Biology
Jana Vitku, Martin Hill, Lucie Kolatorova, Eva Kubala Havrdova, Radmila Kancheva
Summary: This article focuses on the balance of steroid sulfation and desulfation in Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Steroids in the brain and periphery have mutual influence, and play various roles in the nervous system, including effects on neurons and anti-inflammatory actions. The processes of sulfation and desulfation are crucial for the water solubility and transport of steroids.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Medicine, General & Internal
Anna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, Linda Koster, Didier Blaise, Peter Remenyi, Nigel Russell, Per Ljungman, Marek Trneny, Jiri Mayer, Simona Iacobelli, Guido Kobbe, Christof Scheid, Jane Apperley, Cyrille Touzeau, Stig Lenhoff, Esa Jantunen, Achilles Anagnostopoulos, Laura Paris, Paul Browne, Catherine Thieblemont, Nicolaas Schaap, Jorge Sierra, Ibrahim Yakoub-Agha, Laurent Garderet, Jan Styczynski, Helene Schoemans, Ivan Moiseev, Rafael F. Duarte, Zinaida Peric, Silvia Montoto, Anja van Biezen, Malgorzata Mikulska, Mahmoud Aljurf, Tapani Ruutu, Nicolaus Kroeger, Curly Morris, Christian Koenecke, Stefan Schoenland, Grzegorz W. Basak
Summary: This post hoc analysis evaluated the rate of infectious and non-infectious complications after ASCT in multiple myeloma patients. The analysis included 3552 patients and found that complication rates decreased over time. Bacterial infections and gastrointestinal complications were the most common early events. The occurrence of complications was not associated with overall survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Acoustics
Petra Rekova, Gabriela Dostalova, Daniel Rob, Manuela Vaneckova, Martina Pavlicova, Ales Linhart, David Kemlink
Summary: This study compared the cerebrovascular phenotype characteristics between Fabry disease patients and controls using neurosonology. The results showed that Fabry disease patients had more vascular abnormalities and changes in hemodynamic parameters of cerebral arteries compared to the control group.
JOURNAL OF ULTRASOUND IN MEDICINE
(2023)
Correction
Clinical Neurology
Dominika Stastna, Ingrid Menkyova, Jiri Drahota, Tereza Hrnciarova, Eva Kubala Havrdova, Marta Vachova, Michaela Andelova, Pavlina Kleinova, Ivana Kovarova, Eva Krasulova, Jana Lizrova Preiningerova, Iveta Novakova, Klara Novotna, Martina Novotna, Petra Nytrova, Jana Pavlickova, Barbora Srpova, Katerina Storey, Veronika Ticha, Michaela Tyblova, Tomas Uher, Karolina Vodehnalova, Dana Horakova
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Veronica Ravano, Gian Franco Piredda, Jan Krasensky, Michaela Andelova, Tomas Uher, Barbora Srpova, Eva Kubala Havrdova, Karolina Vodehnalova, Dana Horakova, Petra Nytrova, Jonathan A. Disselhorst, Tom Hilbert, Benedicte Marechal, Jean-Philippe Thiran, Tobias Kober, Jonas Richiardi, Manuela Vaneckova
Summary: In this study, the authors investigated the impact of the location of microstructural alterations in neuronal pathways in multiple sclerosis (MS) patients using quantitative MRI. They found that microstructural changes in specific white matter pathways were better predictors of future disability in early MS patients, highlighting the potential of tract-wise analyses in monitoring disease progression.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Petr Holly, Tereza Duspivova, David Kemlink, Olga Ulmanova, Jan Rusz, Radim Krupicka, Robert Jech, Evzen Ruzicka
Summary: This study aimed to investigate which clinical and instrumental methods could best differentiate head tremor in patients with essential tremor (ET) and cervical dystonia (CD). The results showed that patients with head tremor had higher TETRAS and SARA scores, with no significant difference in mild head tremor subscores between the ET and CD groups. Head tremor disappeared when patients were in the supine position, and the STDT values were significantly higher in the group with head tremor.
PARKINSONISM & RELATED DISORDERS
(2023)
Meeting Abstract
Clinical Neurology
T. Kalincik, S. Sharman, I. Roos, M. Freedman, H. Atkins, J. Burman, J. Massey, I. Sutton, B. Withers, R. Macdonell, A. Grigg, O. Torkildsen, L. Bo, A. Lehmann, D. Horakova, E. Havrdova, E. Krasulova, M. Trneny, T. Kozak, A. van der Walt, H. Butzkueven, P. McCombe, B. Van Wijmeersch, K. Buzzard, O. Skibina, J. Lechner-Scott, B. Willekens, M. Barnett, E. Cartechini, S. Ozakbas, R. Alroughani, G. Izquierdo, S. Eichau, C. Boz, J. Kuhle, F. Patti, M. Terzi, A. Prat, M. Girard, P. Duquette, P. Grammond, M. Onofrj, A. Lugaresi, S. Khoury, A. Soysal, M. Slee, J. Prevost, R. Turkoglu, B. Sharrack, J. Snowden
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
T. Kalincik, S. Sharmin, I. Roos, M. S. Freedman, H. Atkins, J. Burman, J. Massey, I. Sutton, B. Withers, R. Macdonell, A. Grigg, O. Torkildsen, L. Bo, A. K. Lehmann, D. Horakova, E. K. Havrdova, E. Krasulova, M. Trneny, T. Kozak, A. van der Walt, H. Butzkueven, B. Van Wijmeersch, P. McCombe, K. Buzzard, O. Skibina, J. Lechner-Scott, B. Willekens, M. Barnett, E. Cartechini, G. Izquierdo, S. Eichau, F. Patti, S. Hodgkinson, J. Prevost, M. Onofrj, A. Lugaresi, R. Alroughani, E. Butler, A. Prat, M. Girard, P. Duquette, P. Grammond, F. Grand'Maison, G. Laureys, L. Van Hijfte, D. Maimone, B. Sharrack, J. Snowden
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
T. Kalincik, S. Sharmin, I. Roos, J. Massey, I. Sutton, B. Withers, M. Freedman, H. Atkins, D. Horakova, E. Kubala Havrdova, E. Krasulova, M. Trneny, T. Kozak, J. Burman, R. Macdonell, A. Grigg, O. Torkildsen, L. Bo, A. K. Lehmann, B. Sharrack, J. Snowden
MULTIPLE SCLEROSIS JOURNAL
(2022)